Search form


Press Releases

Axcan to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, UK

Sep 18, 2006 - 01:45 ET

MONT SAINT-HILAIRE, QUEBEC--(CCNMatthews - Sept. 18, 2006) - Axcan Pharma Inc. ("Axcan" or the "Company") (TSX:AXP) (Nasdaq:AXCA) today announced that on Thursday, September 21, 2006, President and Chief Executive Officer, Frank A.G.M. Verwiel, M.D., will present an overview of the Company at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference to be held in London, United Kingdom. This presentation will take place at 4:40 p.m. BST (11:40 a.m. Eastern time).

A webcast of Axcan's presentation will also be accessible via the Company's website at

Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and Europe. Its common shares are listed on the NASDAQ Global Market under the symbol "AXCA" and on the Toronto Stock Exchange under the symbol "AXP".

Axcan Pharma Inc.
Isabelle Adjahi
Director, Investor Relations
(450) 467-2600 ext. 2000